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Abstract 
Reduced kidney mass and/or function may result in multiple metabolic 
derangements, including insulin resistance. However, underlying mechanisms are poorly 
understood. Herein, we aimed to determine the impact of reduced kidney mass on 
glucose metabolism in lean and obese mice. To that end, seven-week-old C57BL6/J 
mice underwent uninephrectomy (UniNx) or sham operation. After surgery, animals were 
fed either a chow (standard) or a high fat diet (HFD) and glucose homeostasis was 
assessed 20 weeks after surgery. Intraperitoneal glucose tolerance was similar in sham-
operated and UniNx mice. However, insulin-stimulated glucose disposal in vivo was 
significantly diminished in UniNx mice, whereas insulin-stimulated glucose uptake into 
isolated skeletal muscle was similar in sham-operated and UniNx mice. Of note, 
capillary density was significantly reduced in skeletal muscle of HFD-fed UniNx mice. In 
contrast, hepatic insulin sensitivity was improved in UniNx mice. Furthermore, adipose 
tissue HIF1α-expression and inflammation was reduced in HFD-fed UniNx mice. 
Treatment with the angiotensin II receptor blocker telmisartan improved glucose 
tolerance and hepatic insulin sensitivity in HFD-fed sham-operated but not UniNx mice. 
In conclusion, UniNx protects from obesity-induced adipose tissue inflammation and 
hepatic insulin resistance but it reduces muscle capillary density and, thus, deteriorates 
HFD-induced skeletal muscle glucose disposal. 
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Introduction 
Metabolic disorders such as obesity, diabetes, and dyslipidemia may lead to 
progressive renal damage. Conversely, there is increasing evidence that reduced kidney 
function may deteriorate glucose metabolism and insulin sensitivity in humans (1; 2). In 
addition, live kidney donation may increase the risk to develop insulin resistance and the 
metabolic syndrome (3; 4). Such clinical observation is supported by recent 
experimental studies in rats showing the development of glucose intolerance, 
dyslipidemia, and ectopic fat accumulation in parallel with the development of uremia in 
uninephrectomized animals (5; 6). Mechanistically, overnutrition may activate the renin 
angiotensin system (RAS) and, thus, may contribute to the pathogenesis of the 
metabolic syndrome in the presence of reduced renal function. In particular, activation of 
the RAS/angiotensin receptors (ATRs) impairs insulin signaling in adipose tissue, 
skeletal muscle and liver (7) and its prevention by ATR blockade (pharmaceutically or 
genetically) improves glucose homeostasis (8; 9). In particular, the angiotensin II type 1 
receptor blocker telmisartan was previously reported to improve obesity-/HFD-
associated adipose tissue inflammation (10-12). Moreover, uninephrectomized rats 
developed fat redistribution that could be prevented by treatment with an angiotensin-
converting enzyme (ACE)-inhibitor (6). 
Skeletal muscle is the major site of insulin-induced glucose disposal in the 
postprandial state. Besides directly stimulating glucose uptake into muscle fibers, insulin 
increases microvascular blood flow to the muscle accounting for approximately half of 
the insulin-mediated glucose uptake (13). Accordingly, the number of capillaries 
perfusing the muscle is positively related to peripheral insulin action (14). Moreover, 
reduced blood flow to the muscle is correlated with insulin resistance (15-18) and 
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insulin-resistant humans and rodents exhibit capillary rarefaction (19-21). However, it 
still remains unclear whether the reduction in capillaries is a cause or consequence of 
muscle insulin resistance (22). 
In the present study, we sought to determine the impact of reduced kidney mass 
as established by uninephrectomy (UniNx) on glucose metabolism in HFD-fed mice. 
Unexpectedly, we found that UniNx resulted in decreased adipose tissue inflammation 
and improved hepatic insulin sensitivity and steatosis. In contrast, UniNx reduced 
skeletal muscle capillary density and deteriorated muscle insulin action in vivo. 
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Research Design and Methods 
 
Animals 
Male C57BL/6J (C57BL/6JOlaHsd)-mice were purchased from Harlan (AD Horst, 
The Netherlands). All mice were housed in a specific pathogen-free environment on a 
12-hourlight-dark cycle (light on from 7 pm to 7 am) and fed ad libitum with regular chow 
diet (ProvimiKliba, Kaiseraugst, Switzerland) or high fat diet (HFD) (58 kcal% fat 
w/sucrose Surwit Diet, D12331, Research Diets). All protocols conformed to the Swiss 
animal protection laws and were approved by the Cantonal Veterinary Office in Zurich, 
Switzerland. 
 
Surgical procedures 
Male C57BL/6J mice underwent uninephrectomy or sham operation at seven 
weeks of age. Mice were anesthetized with isoflurane (Abbott, Baar, Switzerland). Mice 
were placed on a warming-pad and kept under an infrared heating lamp to stabilize body 
temperature during the whole surgical procedure. Left nephrectomy was performed 
through a 1.0 cm incision on left dorsolateral paralumbar region as follows. After skin 
incision, abdominal muscles were incised to expose retroperitoneal region. Left kidney 
was secured with a clamp (FRANCIS chalazion forceps, D-8425) and fat attached to 
kidney was removed. Special care was taken to prevent damage to the adrenal gland. 
Renal blood vessels and ureter were ligated with sterile silk surgical sutures. 
Subsequently, left kidney was excised distal to ligatures. Abdominal muscles were sewn 
with reabsorbal thread and opposite ends of incised skin was clipped together using 
sterile disposable skin staplers. Sham-operated control mice underwent identical 
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surgical procedure except for kidney removal. Subcutaneous injection of buprenorphine 
(Essex, Luzern, Switzerland) every 6 hours for 2 days was used for analgesia. 
 
Intra-peritoneal glucose and insulin tolerance tests 
For intraperitoneal glucose tolerance test (ipGTT) mice were fasted overnight and 
for intraperitoneal insulin tolerance tests (ipITT) for 3h. Either glucose (2 g/kg body 
weight) or human recombinant insulin (1.0 U/kg body weight) were injected 
intraperitoneally (23).  
 
Glucose clamp studies 
Glucose clamp studies were performed as described (24). Clamps were 
performed in freely moving mice. Glucose infusion rate was calculated once glucose 
infusion reached a more or less constant rate with blood glucose levels at 5 mmol/l (80–
90 min after the start of insulin infusion). Thereafter, blood glucose was kept constant at 
5 mmol/l for 20 min and glucose infusion rate was calculated. The glucose disposal rate 
was calculated by dividing the rate of [3-3H]glucose infusion by the plasma [3-3H]glucose 
specific activity (25). Endogenous glucose production during the clamp was calculated 
by subtracting the glucose infusion rate from the glucose disposal rate (25; 26). Insulin-
stimulated glucose disposal rate was calculated by subtracting basal endogenous 
glucose production (equal to basal glucose disposal rate) from glucose disposal rate 
during the clamp (27). In order to assess tissue specific glucose uptake, a bolus (10 µCi) 
of 2-[1-14C]deoxyglucose was administered via catheter at the end of the steady state 
period. Blood was sampled 2, 15, 25 and 35 min after bolus delivery. Area under the 
curve of disappearing plasma 2-[1-14C]deoxyglucose was used together with tissue-
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concentration of phosphorylated 2-[1-14C]deoxyglucose to calculate glucose uptake, as 
was previously described (28). 
 
Metabolic cage analysis 
Locomotion, food intake, O2 consumption and CO2 production were determined 
for single housed mice during a 24-h period in a metabolic and behavioral monitoring 
system (PhenoMaster, TSE Systems, Bad Homburg, Germany) as described (29). 
 
Determination of insulin, free fatty acid, angiotensin I, creatinine, uric acid and bile acid 
levels 
Plasma insulin and free fatty acid levels were determined as described (23). 
Plasma angiotensin I levels were determined by an ELISA kit (Cusabio Biotech CO Ltd, 
Wuhan, PR China). Serum creatinine levels were measured using DetectX® Low 
Sample Volume Serum Creatinine Kit (K0021-H1D, Arbor Assays, Ann Arbor, MI, USA), 
serum uric acid levels by QuantiChromTM Uric Acid Assay Kit (DIUA-250, BioAssay 
Systems, Hayward, CA, USA) and plasma bile acid levels using Mouse Total Bile Acids 
Assay Kit (80470, Crystal Chem Inc, Downers Grove, IL, USA). 
 
Glucose incorporation into isolated soleus and EDL muscle 
Mice were fasted for 4 h prior to the analysis. EDL and soleus muscles were 
removed from anesthetized mice (Avertin, 99% 2,2,2-tribromo ethanol, and tertiary amyl 
alcohol at 15–17 µl/g body weight ip) and incubated for 30 min at 30°C in vials 
containing preoxygenated (95% O2-5% CO2) Krebs-Henseleit buffer (KHB) containing 5 
mM HEPES (prebuffer) and supplemented with 15 mM mannitol and 5 mM glucose. 
Page 7 of 44 Diabetes
 8
Muscles were transferred to new vials containing fresh pre-gassed KHB, as described 
above with or without 120nM of insulin (Actrapid; Novo Nordisk, Mainz, HE, Germany). 
Afterwards, muscles were transferred to new vials containing preoxygenized KHB 
supplemented with 20 mM mannitol and incubated for 10 min. Muscles were then 
transferred to new vials containing preoxygenized KHB supplemented with 1 mM [3H]2-
deoxy-glucose (2.5 µCi/ml), and 19mM [14C]mannitol to account for extracellular space, 
and incubated for 20 min. After the last incubation, muscles were washed in ice-cold 
KHB, dried externally on filter paper, and quickly frozen with aluminum tongs precooled 
in liquid nitrogen and stored at −80°C. Glucose transport rates were determined by 
scintillation counting of cleared protein lysates as described (30).  
 
Insulin signaling in skeletal muscle ex vivo 
For assessing insulin-stimulated Akt phosphorylation in skeletal muscle, insulin 
(2U/kg) was injected i.p. in mice fasted for 5 hours. Skeletal muscles (quadriceps) were 
harvested 15 minutes after insulin injection, snap frozen in liquid nitrogen and stored at -
80°C until homogenization.  
 
Histology 
Fat tissues were fixed in 4% buffered formalin and embedded in paraffin. 
Sections were cut and stained with hematoxylin and eosin. For each fat pad at least 100 
adipocytes were analyzed. Quadriceps femoris muscle was mounted in embedding 
medium (o.c.t. embedding matrix, CellPath Ltd., Newtown, UK), snap frozen in 
isopentane cooled to -160°C with liquid nitrogen, and subsequently stored at -80°C until 
use. Consecutive 12 µm sections were cut on a microtome at -25°C. Rat anti-mouse 
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CD31 endothelial cell antibody (BioLegend, San Diego, CA) was used as a marker for 
muscle capillaries, and capillary-to-fiber ratio was calculated by dividing the number of 
CD31-positive cells by the number of muscle fibers. For all histochemical and 
immunohistochemical analyses NIH Image J software (National Institutes of Health, 
Bethesda, MD) was used. 
 
Total liver lipid and triglyceride determination 
Liver tissue (10-30mg) was homogenized in PBS and lipids were extracted in a 
chloroform-methanol (2:1) mixture. Total liver lipids were determined by a 
sulfophosphovanillin reaction as previously described (31). Liver triglycerides were 
measured from 50 mg of liver tissue using a variation of the Bligh and Dyer method (32) 
and quantified with an enzymatic assay (Roche Diagnostics, Rotkreuz, Switzerland). 
 
RNA extraction and quantitative reverse transcription-PCR (RT-PCR). 
Total RNA was extracted and reverse transcribed as described (33). The 
following primers were used: TNF-α Mm00443258_m1, IL-6 Mm00446190_m1, IL-1β 
Mm0043422/8_m1, cd11c Mm00498698_m1, ATGL Mm00503040_m1, perilipin 
Mm00558672_m1, HIF1α Mm00468869_m1, CD31 Mm01242584_m1, VEGF-A 
Mm01281441_m1 (Applied Biosystems, Rotkreuz, Switzerland). 
 
Western Blotting 
Cells or tissues were lysed and Western blots were performed as previously 
described (33). The following primary antibodies were used: anti-phospho-Akt (Ser473), 
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anti-total Akt (Cell Signaling, Danvers, MA, USA), anti-VEGF-A (Santa Cruz 
Biotechnology Inc., Dallas, TX, USA) and anti-actin (Millipore, Zug, Switzerland). 
 
Data analysis 
Data are presented as mean +/- SEM and were analyzed by unpaired Student’s t 
test. p-Values < 0.05 were considered significant. 
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Results 
 
Improved hepatic but deteriorated muscle insulin sensitivity in HFD-fed UniNx mice  
Surgical procedure (sham operation or UniNx) was performed in C57BL6/J mice 
at seven weeks of age. Mice were fed either normal chow or HFD for 20 weeks. Total 
body weight gain was similar in sham-operated and UniNx mice under both diets (Table 
1). After 20 weeks of HFD, inguinal and mesenteric fat pad weights in the UniNx mice 
were comparable to sham-operated mice, whereas epididymal fat pad weight was 
significantly higher in UniNx mice (Table 1). No differences in fat pad weights were 
observed between chow-fed sham-operated and UniNx mice (Table 1). In addition, food 
intake, locomotion, or fuel utilization (respiratory quotient, RQ) was similar between 
HFD-fed sham-operated and UniNx mice (Supplementary Figure 1). 
Fasting blood glucose levels were similar between HFD-fed sham-operated and 
UniNx mice (Table 2). In addition, plasma insulin and free fatty acid (FFA) 
concentrations did not differ significantly between both groups (Table 2). Glucose and 
insulin tolerance were similar in UniNx mice compared to sham-operated mice under 
both standard chow as well as HFD 20 weeks after surgery (Figures 1A and 1B). 
Hyperinsulinemic-euglycemic clamp studies revealed similar glucose infusion rate in 
HFD-fed UniNx compared to sham-operated mice (see Figure 1C for steady-state 
glucose infusion rates and Supplementary Figure 2 for detailed time courses). 
Importantly, insulin-induced suppression of endogenous glucose production (mainly 
reflecting hepatic glucose production) was blunted in HFD-fed sham-operated mice, but 
was clearly evident in UniNx mice (Figure 1D) indicating improved/preserved hepatic 
insulin sensitivity in the latter. In contrast, glucose disposal rate during hyperinsulinemic-
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euglycemic clamp was significantly further deteriorated in HFD-fed UniNx mice 
suggesting reduced skeletal muscle insulin sensitivity compared to sham-operated mice 
(Figure 1E).  
 
Improved hepatic steatosis in HFD-fed UniNx mice  
Hepatic insulin sensitivity is often associated with hepatic steatosis, though it is 
still debated whether insulin resistance is the cause of hepatic steatosis, or whether the 
increase in triglycerides (or of lipid metabolites such as ceramides, diacylglycerol and 
acyl-CoAs) causes the development of hepatic and/or systemic insulin resistance. As 
depicted in Figure 2A, total liver lipid content was greatly reduced in HFD-fed UniNx 
compared to sham-operated mice. Similarly, liver triglyceride levels were reduced in 
HFD-fed UniNx mice (UniNx mice: 234.5 ± 41.0 µmol/g liver; sham-operated mice: 401.3 
± 77.5 µmol/g liver). In addition, histological examination of liver sections revealed 
reduced frequency of lipid vacuoles in HFD-fed UniNx mice (Figure 2B). 
 
Reduced adipose tissue inflammation in HFD-fed UniNx mice  
The ‘portal theory’ proposes that the direct exposure of the liver to increasing 
amounts of FFA and/or pro-inflammatory factors released from visceral fat into the portal 
vein may promote the development of hepatic insulin resistance and steatosis (34). 
Accordingly, mRNA expression of pro-inflammatory cytokines as well as adipose tissue 
histology was analyzed in order to characterize adipose tissue inflammation. As 
depicted in Figure 2C, expression of CD11c (a marker for pro-inflammatory M1 polarized 
macrophages) and interleukin-6 (IL-6) was significantly decreased and expression of 
tumor-necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) trendwise reduced in 
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mesenteric adipose tissue of HFD-fed UniNx compared to sham-operated mice. Of note, 
mRNA levels of the hypoxia-inducible factor 1α (HIF1α) was significantly lower in 
mesenteric adipose tissue of HFD-fed UniNx mice (Figure 2C). In contrast, adipocyte 
size was not different between both groups of mice (Figures 2D and 2E). In addition, 
insulin-stimulated Akt-phosphorylation in adipose tissue was similar in both groups 
suggesting similar insulin sensitivity in this tissue (Figure 2F). Thus, uninephrectomy 
protects mice from the development of HFD-induced adipose tissue inflammation and 
consequently hepatic insulin resistance. 
 
Similar skeletal muscle insulin action in vitro  
Glucose uptake into isolated soleus (slow-twitch) and extensor digitorum longus 
(fast-twitch) muscles was assessed next removing extramyocellular barriers to muscle 
glucose uptake. As depicted in Figure 3A and B, basal and insulin-stimulated glucose 
uptake were similar between HFD-fed sham-operated and UniNx mice, suggesting no 
direct impairment of insulin action at the myocyte level. Of note, 20 weeks of HFD led to 
an expected poor insulin response in skeletal muscle, which was particularly evident in 
soleus muscle. Similar to ex vivo glucose uptake, no difference between both groups of 
mice was found for in vivo insulin-stimulated Akt phosphorylation in total muscle 
homogenates (Figure 3C). These data in isolated muscle contrasts the data obtained 
from hyperinsulinemic-euglycemic clamp studies revealing diminished muscle insulin 
sensitivity in HFD-fed UniNx mice and may indicate that UniNx leads to impaired insulin 
delivery to the sarcolemma, e.g. through reduction in capillary density.  
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Reduced capillary density in skeletal muscle of HFD-fed UniNx mice  
In order to assess capillary density, expression of the endothelial marker CD31 
was determined. As depicted in Figure 4A, mRNA levels of CD31 were significantly 
reduced in quadriceps muscle in HFD-fed UniNx compared to sham-operated mice 
whereas no difference was observed in chow-fed mice (Supplementary Figure 3). 
Moreover, capillary-to-fiber ratio was significantly (~ 15%) reduced in skeletal muscle of 
HFD-fed UniNx mice (Figures 4B and 4C). Thus, uninephrectomy reduces muscle 
capillary density in HFD-fed mice. Mechanistically, reduced muscle capillary density may be 
the result of reduced HIF1α levels, which is a transcriptional activator of genes encoding 
vascular endothelial growth factor (VEGF) and other important mediators of angiogenesis (35). 
Indeed, HIF1α and VEGF-A mRNA levels were decreased in skeletal muscle of HFD-fed UniNx 
mice (Figure 4D). Moreover, protein levels of VEGF-A were decreased by 40% in skeletal 
muscle of HFD-fed UniNx compared to sham-operated mice (Figure 4E). 
 
Improved hepatic insulin sensitivity in telmisartan-treated HFD-fed sham-operated mice  
As reported in Table 2, angiotensin I levels were significantly increased in HFD-
fed UniNx mice. Activation of the renin-angiotensin system (RAS) was previously 
suggested to contribute to HFD-associated skeletal muscle insulin resistance (36-38). 
Thus, we hypothesized that the observed increase in circulating angiotensin I 
concentration may deteriorate HFD-induced skeletal muscle insulin resistance via 
activation of angiotensin II type 1 receptors (AT1R). To test such hypothesis we made 
use of the AT1R blocker telmisartan. UniNx and sham-operated mice were fed a HFD 
for 20 weeks and received telmisartan in the drinking water at a dose of 3mg/kg*day 
during the entire period. As depicted in Figures 5A and 5B telmisartan treatment 
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improved glucose tolerance in HFD-fed sham-operated but not UniNx mice. Moreover, it 
improved glucose infusion rate (Figure 5C) and hepatic insulin sensitivity (Figure 5D) in 
sham-operated mice as analyzed by hyperinsulinemic-euglycemic clamp studies (see 
Supplementary Figure 4 for detailed time courses). In accordance with elevated hepatic 
insulin sensitivity, telmisartan treatment reduced hepatic steatosis in sham-operated 
mice (total liver lipids in untreated HFD-fed sham-operated mice: 299.4 ± 59.6 mg/g liver 
tissue; total liver lipids in telmisartan-treated HFD-fed sham-operated mice: 158.0 ± 31.8 
mg/g liver tissue) but did not affect it in UniNx mice (total liver lipids in untreated HFD-
fed UniNx mice: 123.4 ± 17.7 mg/g liver tissue; total liver lipids in telmisartan-treated 
HFD-fed UniNx mice: 178.5 ± 22.8 mg/g liver tissue) resulting in similar total liver lipids 
in telmisartan-treated mice of both groups (Figure 5E). Moreover, mRNA expression 
levels of pro-inflammatory cytokines in mesenteric adipose tissue were similar between 
telmisartan-treated HFD-fed sham-operated and UniNx mice (Figure 5F). Of note, 
expression of HIF1α was no longer different between telmisartan-treated sham-operated 
and UniNx mice (Figure 5F). Such data suggest that telmisartan treatment improved 
adipose tissue inflammation in HFD-fed sham-operated mice since the observed 
difference in cytokine mRNA expression in untreated mice (Figure 2A) was no longer 
present.  
 
No effect of telmisartan treatment on muscle insulin resistance and capillary rarefaction 
in HFD-fed UniNx mice 
Previously, the angiotensin II receptor blocker losartan was found to reverse 
insulin resistance through the modulation of muscular circulation in rats with impaired 
glucose metabolism (20). We therefore postulated that telmisartan would improve 
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muscle insulin sensitivity as well as capillary density in UniNx mice. However, as 
depicted in Figure 6A, 20 weeks of telmisartan treatment did not affect insulin-stimulated 
glucose disposal rate (IS-GDR) in UniNx mice (IS-GDR in untreated HFD-fed UniNx 
mice: 10.6 ± 1.2 mg/kg*min; IS-GDR in telmisartan-treated HFD-fed UniNx mice: 4.2 ± 
2.3 mg/kg*min). Accordingly, insulin stimulated glucose uptake was significantly higher 
in telmisartan-treated HFD-fed sham-operated compared to UniNx mice (Figure 6B). 
Moreover, CD31 expression remained reduced in quadriceps muscle of telmisartan-
treated HFD-fed UniNx compared to sham-operated mice (Figure 6C). Thus, telmisartan 
treatment positively impacts on total body and hepatic insulin sensitivity in HFD-fed 
sham-operated mice but does not affect impaired skeletal muscle insulin sensitivity in 
HFD-fed UniNx mice. 
 
 
Discussion 
In the present study we describe an unexpected dissociation of hepatic and 
muscle insulin resistance: whereas uninephrectomy protected HFD-fed mice from the 
development of hepatic insulin resistance (and hepatic steatosis), it deteriorated skeletal 
muscle insulin resistance.    
The observed association of reduced visceral adipose tissue inflammation and 
improved hepatic insulin sensitivity in HFD-fed UniNx mice is in accordance with the 
“portal theory” claiming that the exaggerated release of FFAs and/or pro-inflammatory 
cytokines from visceral fat are directly delivered to the liver via portal vein, promoting the 
development of hepatic insulin resistance and hepatic steatosis (34). Interestingly, 
expression of HIF1α was reduced in adipose tissue of UniNx mice. Selective inhibition of 
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HIF1α was previously reported to reduce adipose tissue inflammation as well as hepatic 
steatosis in HFD-fed mice (39). Conversely, overexpression of HIF1α induced adipose 
tissue fibrosis and inflammation as well as hepatic steatosis (40). Thus, uninephrectomy 
is associated with decreased HIF1α expression in adipose tissue and thereby may 
contribute to reduced adipose tissue inflammation and, consequently, preserved hepatic 
insulin sensitivity. Such notion is further supported by the fact that treatment with 
telmisartan abolished differences in mRNA expression of HIF1α as well as pro-
inflammatory cytokines and improved hepatic insulin sensitivity in sham-operated mice. 
The kidney contributes to a significant part (~15-20%) to endogenous glucose production 
in both humans and rats (41; 42). Thus, basal endogenous glucose production may be reduced 
in UniNx mice. However, similar basal endogenous glucose production was observed in HFD-
fed UniNx and sham-operated mice (UniNx: 25.8 mg/kg*min, sham-operated: 22.2 mg/kg*min; 
p=0.27). Moreover, insulin-mediated suppression of endogenous glucose production was 
increased in HFD-fed UniNx mice. Since renal glucose production is inhibited by insulin we 
cannot exclude that such improvement may be due to improved renal insulin sensitivity in UniNx 
mice. However, the fact that adipose tissue inflammation as well as liver lipid accumulation was 
decreased in HFD-fed UniNx mice and the notion that endogenous glucose production mainly 
reflects hepatic glucose production renders improved hepatic insulin sensitivity a more likely 
explanation herein.  
Decreased mRNA expression and histological staining of CD31 point towards 
reduced capillary density in skeletal muscle of HFD-fed UniNx mice. Capillary rarefaction 
was previously associated with insulin resistance both in humans and rodents (19-21). 
In accordance with our findings presented herein, Flisinski et al reported reduced 
numbers of capillaries as well as a decreased capillary-to-fiber ratio in gastrocnemius 
and longissimus muscle in UniNx male Wistar rats (43). Such changes were already 
Page 17 of 44 Diabetes
 18
present at an early stage and independent of blood pressure. Of note, treatment with the 
angiotensin II receptor blocker telmisartan had no impact on capillary density in UniNx 
mice suggesting that UniNx-associated capillary rarefaction is not dependent on 
activation of the RAS whereas it may modulate muscular circulation and thereby insulin 
sensitivity as was previously reported for the angiotensin II receptor blocker losartan in 
rats (20). Herein, reduced capillary density was associated with decreased HIF1α mRNA 
expression in skeletal muscle of UniNx mice. HIF1α is the master regulator of 
transcriptional responses to hypoxia and a transcriptional activator of genes encoding 
vascular endothelial growth factor (VEGF) and other important mediators of 
angiogenesis (35). Indeed, VEGF-A mRNA and protein levels were reduced in HFD-fed 
UniNx compared to sham-operated mice suggesting that reduced HIF1α may be 
responsible for reduced capillary density in the former. Importantly, UniNx and subtotal 
nephrectomy in Wistar rats were associated with reduced expression of HIF1α, VEGF A 
and VEGF receptor in gastrocnemius muscle (44). In addition, subtotal nephrectomy 
reduced skeletal muscle angiogenesis in rats (45). Unfortunately, HIF1α expression was 
not determined in the latter publication. Moreover, muscle-specific deletion of VEGF 
resulted in capillary rarefaction and diminished insulin-induced muscle glucose uptake in 
vivo independent of defects in insulin action at the myocyte (22). Thus, reduced 
expression of HIF1α may be causally linked to reduced capillary density observed in 
skeletal muscle of UniNx mice. 
In conclusion, UniNx unexpectedly protects mice from HFD-induced adipose 
tissue inflammation and hepatic insulin resistance potentially via a reduction in HIF1α 
expression. In contrast, UniNx leads to capillary rarefaction in skeletal muscle and, thus, 
deteriorates HFD-induced skeletal muscle glucose disposal in vivo. 
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Figure Legends 
 
Figure 1 Improved hepatic but deteriorated muscle insulin sensitivity in HFD-
fed UniNx mice  
Intra-peritoneal glucose (A) and insulin tolerance (B) tests in chow-fed and HFD-fed 
sham-operated and UniNx mice are shown. Black squares: chow sham-operated (n=7); 
grey squares: chow UniNx (n=6); black circles: HFD sham-operated (n=15-17); grey 
circles: HFD UniNx (n=14-17). (C to E) Glucose infusion rate, inhibition of endogenous 
glucose production and insulin-stimulated glucose disposal rate (IS GDR) during 
hyperinsulinemic-euglycemic clamps in HFD-fed mice (n=5). Error bars represent SEM. 
*p < 0.05 and **p < 0.01 (Student’s t-test). 
 
Figure 2 Reduced hepatic steatosis and adipose tissue inflammation in HFD-fed 
UniNx mice  
(A) Total liver lipids were determined and expressed relative to total liver weight in HFD-
fed sham-operated (black bars) and UniNx mice (grey bars). (B) Representative 
hematoxylin- and eosin-stained histological sections of liver of HFD-fed sham-operated 
and UniNx mice. Scale bar represents 50 µm. (C) mRNA expression of respective genes 
in mesenteric adipose tissue of HFD-fed sham-operated (black bars) and UniNx mice 
(grey bars). n=5-10. *p < 0.05 (Student’s t-test). (D) Representative hematoxylin- and 
eosin-stained histological sections of epididymal adipose tissue of HFD-fed sham-
operated and UniNx mice. Scale bar represents 100 µm. (E) Adipocyte cell perimeter 
was measured using ImageJ. Up to 100 cells per fat pad of four different mice per group 
were analyzed. (F) Lysates of white adipose tissue were prepared, resolved by LDS-
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PAGE and immunoblotted with anti-pS473 Akt, anti-total Akt or anti-actin antibody. 
Graphs show results of 4-5 mice.  *p < 0.05 (Student’s t-test). All error bars represent 
SEM. 
 
Figure 3 Preserved/sustained insulin-stimulated glucose uptake into skeletal 
muscle ex vivo  
Glucose uptake into intact isolated soleus muscle (A) and extensor digitorum longus 
(EDL) muscle (B) was measured in the absence (open bars) or presence of 120 nM 
insulin (filled bars). n=8. (C) Total muscle lysates were prepared, resolved by LDS-
PAGE and immunoblotted with anti-pS473 Akt, anti-total Akt or anti-actin antibody. 
Graphs show results of 4-5 mice. Error bars represent SEM. 
 
Figure 4 Reduced capillary density in skeletal muscle of HFD-fed UniNx mice  
(A) mRNA expression of CD31 in quadriceps muscle of HFD-fed sham-operated (black 
bars) and UniNx mice (grey bars). n=4-5. (B and C) CD31 staining of quadriceps muscle 
harvested from HFD-fed sham-operated and UniNx mice. Capillary-to-fiber ratio was 
calculated after counting up to 700 fibers and corresponding capillaries per mouse. 
Scale bar represents 100 µm. n=4. (D) mRNA expression of HIF1α and VEGF-A in 
quadriceps muscle of HFD-fed sham-operated (black bars) and UniNx mice (grey bars). 
n=4-5. (E) Total muscle lysates were prepared, resolved by LDS-PAGE and 
immunoblotted with anti-VEGF-A or anti-actin antibody. Graphs show results of 8 mice. 
Error bars represent SEM. § p = 0.07, # p = 0.06, *p < 0.05 (Student’s t-test). 
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Figure 5 Improved hepatic insulin sensitivity in telmisartan-treated HFD-fed 
sham-operated mice  
(A) Intra-peritoneal glucose-tolerance test in telmisartan-treated HFD-fed sham-
operated (black circles) and UniNx (grey circles) mice. n=9-11. (B) Analysis of the area 
under the curve of glucose tolerance tests presented in A. (C) Glucose infusion rate and 
(D) inhibition of endogenous glucose production during hyperinsulinemic-euglycemic 
clamps. n=4. (E) Total liver lipids were determined and expressed relative to total liver 
weight in telmisartan-treated HFD-fed sham-operated (black bars) and UniNx mice (grey 
bars). n=5-6. All error bars represent SEM. (F) mRNA expression of respective genes in 
mesenteric adipose tissue of telmisartan-treated HFD-fed sham-operated (black bars) 
and UniNx mice (grey bars). n=4-5.Error bars represent SEM. *p < 0.05 and **p < 0.01 
(Student’s t-test). 
 
Figure 6 No effect of telmisartan treatment on muscle insulin resistance and 
capillary rarefaction in HFD-fed UniNx mice 
(A) Insulin-stimulated glucose disposal rate (IS GDR) and (B) insulin-stimulated glucose 
uptake into quadriceps muscle during hyperinsulinemic-euglycemic clamps. n=4. (C) 
mRNA expression of CD31 and HIF1α in quadriceps muscle of HFD-fed telmisartan-
treated sham-operated (black bars) and UniNx mice (grey bars). n=4-5. *p < 0.05 and 
**p < 0.01 (Student’s t-test). 
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Table 1 Body and organ weight in sham-operated and UniNx mice 
 
 Sham-operated UniNx 
 Chow HFD Chow HFD 
Body weight (g) 
- before surgery 
- 20 weeks after 
N 
 
24.5 ± 1.0 
35.2 ± 0.7  
7 
 
25.1 ± 0.6 
51.2 ± 1.0 
22 
 
24.4 ± 0.6 
33.3 ± 0.7 
8 
 
25.1 ± 0.8 
50.4 ± 1.0 
22 
Kidney weight (mg) 
- right kidney 
- left kidney 
N 
 
212 ± 6 
203 ± 5 
7 
 
231 ± 6 
209 ± 6 
8 
 
269 ± 7*** 
- 
8 
 
284 ± 11*** 
- 
7 
Liver weight (mg) 
N 
1576 ± 11.7 
7 
2458 ± 192## 
13 
1454 ± 45 
8 
2169 ± 145## 
12 
Fat pad weight (mg) 
- inguinal 
- epididymal 
- mesenteric 
N 
 
576 ± 74 
899 ± 97 
719 ± 158 
7 
 
2479 ± 140### 
1857 ± 103### 
1416 ± 89### 
13 
 
428 ± 75 
887 ± 156 
523 ± 59 
8 
 
2362 ± 97### 
2382 ± 150**,### 
1389 ± 131### 
12 
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*p<0.05, **p<0.01, ***p<0.001 compared to sham-operated mice; #p<0.05, ##p<0.01, 
###p<0.001 compared to chow-fed mice. 
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Table 2 Circulating blood levels in sham-operated and UniNx mice 
 
 Sham-operated UniNx 
 Chow HFD Chow HFD 
Glucose (mmol/l) 
N 
7.8 ± 0.7 
7 
11.7 ± 0.8## 
10 
8.8 ± 0.4 
8 
11.9 ± 0.8## 
10 
Insulin (ng/ml) 
N 
1.6 ± 0.2 
7 
7.0 ± 0.6### 
10 
0.9 ± 0.1** 
8 
5.9 ± 0.8### 
10 
FFA (mmol/l) 
N 
n.d. 
 
0.72 ± 0.9 
5 
n.d. 
 
0.79 ± 0.9 
5 
Creatinine (mg/dl) 
N 
n.d. 
 
0.59 ± 0.03 
7 
n.d. 
 
0.72 ± 0.03* 
9 
Uric acid (mg/dl) 
N 
n.d. 
 
4.4 ± 0.4 
8 
n.d. 
 
5.4 ± 0.8 
9 
Angiotensin I (ng/ml) 
N 
20.9 ± 2.0 
6 
20.6 ± 1.5 
8 
29.4 ± 1.8** 
6 
26.5 ± 1.5* 
9 
Bile acids (µmol/l) 
N 
8.4 ± 3.1 
7 
9.4 ± 1.3 
10 
8.2 ± 2.3 
8 
14.0 ± 4.0 
10 
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*p<0.05, **p<0.01, ***p<0.001 compared to sham-operated mice; #p<0.05, ##p<0.01, 
###p<0.001 compared to chow-fed mice. 
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intake was measured in metabolic cages in HFD-fed sham-operated (black bars) and 
UniNx (grey bars) mice. n=7-8. Error bars represent SEM. 
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Supplementary Figure 2 
Blood glucose concentrations and glucose infusion rates during 
hyperinsulinemic-euglycemic clamp 
(A) Blood glucose levels were clamped upon insulin infusion at about 5 mmol/l in HFD-
fed sham (black symbols) and UniNx (grey symbols) mice. n=5. (B) In order to maintain 
euglycemia, glucose infusion rate was adjusted over time. n=5. 
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Supplementary Figure 3 
Similar CD31 and HIF1α mRNA expression in chow-fed sham-operated and UniNx 
mice 
mRNA expression of CD31 and HIF1α in quadriceps muscle of chow-fed sham-operated 
(black bars) and UniNx mice (grey bars). n=5.  
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Supplementary Figure 4 
Blood glucose concentrations and glucose infusion rates during 
hyperinsulinemic-euglycemic clamp in telmisartan-treated HFD-fed mice 
(A) Blood glucose levels were clamped upon insulin infusion at about 5 mmol/l in 
telmisartan-treated HFD-fed sham (black circles) and UniNx (grey circles) mice. n=5. 
(B) In order to maintain euglycemia, glucose infusion rate was adjusted over time. n=5. 
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